Primary and metastatic brain cancer genomics and emerging biomarkers for immunomodulatory cancer treatment
| العنوان: | Primary and metastatic brain cancer genomics and emerging biomarkers for immunomodulatory cancer treatment |
|---|---|
| المؤلفون: | Angela Listì, Christian D. Rolfo, Francesco Passiglia, Ignacio Gil-Bazo, Luis E. Raez, Antonio Russo, Paolo Manca, Joseph A. Pinto, Simona Taverna, Elisa Giovannetti, Christian Caglevic |
| المساهمون: | Passiglia, F., Caglevic, C., Giovannetti, E., Pinto, JA., Manca, P., Taverna, S., Listì, A., Gil-Bazo, I., Raez, LE., Russo, A., Rolfo, C. |
| المصدر: | Seminars in cancer biology Passiglia, F, Caglevic, C, Giovannetti, E, Pinto, J A, Manca, P, Taverna, S, Listì, A, Gil-Bazo, I, Raez, L E, Russo, A & Rolfo, C 2018, ' Primary and metastatic brain cancer genomics and emerging biomarkers for immunomodulatory cancer treatment ', Seminars in Cancer Biology, vol. 52, no. Pt 2, pp. 259-268 . https://doi.org/10.1016/j.semcancer.2018.01.015Test |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | 0301 basic medicine, Cancer Research, Settore MED/06 - Oncologia Medica, medicine.medical_treatment, Biomarkers, Brain, CTLA4, Immunotherapy, Metastasis, PD1/PDL1, Genomics, Metastasi, Immunomodulation, 03 medical and health sciences, 0302 clinical medicine, medicine, Biomarkers, Tumor, Cytotoxic T cell, Animals, Humans, Primary (chemistry), business.industry, Brain Neoplasms, Immunogenicity, Biomarker, medicine.disease, Cancer treatment, 030104 developmental biology, 030220 oncology & carcinogenesis, Toxicity, Cancer research, Human medicine, business |
| الوصف: | Recent studies with immunomodulatory agents targeting both cytotoxic T-lymphocyte protein 4 (CTLA4) and programmed cell death 1 (PD1)/programmed cell death ligand 1 (PDL1) have shown to be very effective in several cancers revealing an unexpected great activity in patients with both primary and metastatic brain tumors. Combining anti-CTLA4 and anti-PD1 agents as upfront systemic therapy has revealed to further increase the clinical benefit observed with single agent, even at cost of higher toxicity. Since the brain is an immunological specialized area it's crucial to establish the specific composition of the brain tumors' micro environment in order to predict the potential activity of immunomodulatory agents. This review briefly summarizes the basis of the brain immunogenicity, providing the most updated clinical evidences in terms of immune-checkpoint inhibitors efficacy and toxicity in both primary and metastatic brain tumors with the final aim of defining potential biomarkers for immunomodulatory cancer treatment. |
| وصف الملف: | |
| اللغة: | English |
| تدمد: | 1044-579X |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40b71b1dfaf531ceed0915a34a319060Test https://hdl.handle.net/10067/1547650151162165141Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....40b71b1dfaf531ceed0915a34a319060 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 1044579X |
|---|